Jury Still Out on Anthracyclines in HER2+ Breast Cancer

COMMENTARY

Jury Still Out on Anthracyclines in HER2+ Breast Cancer

Kathy D. Miller, MD; Sara Tolaney, MD, MPH

Disclosures

December 15, 2015

1
This feature requires the newest version of Flash. You can download it here.

Kathy D. Miller, MD: Hi. I'm Kathy Miller, professor of medicine and co-director of the Simon Cancer Center Breast Cancer Program at the Indiana University School of Medicine in Indianapolis.

Welcome to Medscape Oncology Insights and the 2015 San Antonio Breast Cancer Symposium. The meeting is just underway. As has been the case in the last couple of years, HER2-positive disease is a major focus of our discussions and a major focus of the work at this meeting.

Joining me to put these studies into perspective is Dr Sara Tolaney, senior physician and associate director of clinical research in the Susan Smith Center at the Dana-Farber Cancer Institute in Boston. Welcome, Sara.

Sara Tolaney, MD, MPH: Thank you.

10-Year Results: Still No Definitive Answer on Anthracyclines

Dr Miller: One of the areas of controversy for the last 10 years is whether anthracyclines have a role in the treatment of patients with HER2-positive disease. That controversy was first brought to the forefront by the first results of the BCIRG 006 study,[1] which used a non-anthracycline-containing regimen compared with an anthracycline-trastuzumab regimen. We have the 10-year results at this meeting.[2] Do those 10-year results resolve the controversy?

Dr Tolaney:I think, unfortunately, they do not.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....